The NYT reports on how drug companies are getting access to databases that allow them to track individual doctors' prescribing practices. This information can be helpful in better pitching their drugs to doctors. This is yet another abuse of the sort that economists predict happens when the government imposes monopolies (i.e. patents) that raise prices far above marginal cost. If economists paid attention to the $300 billion industry, they would be looking for more efficient mechanisms for financing prescription drug research.

Leave your comments

Post comment as a guest

0
  • No comments found

GuideStar Exchange Gold charity navigator LERA cfc IFPTE

contact us

1611 Connecticut Ave., NW
Suite 400
Washington, DC 20009
(202) 293-5380
info@cepr.net

let's talk about it

Follow us on Twitter Like us on Facebook Follow us on Tumbler Connect with us on Linkedin Watch us on YouTube Google+ feed cepr.net rss feed